VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease
A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 130 participants.
Also called NCT06249165
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 130 participants
- Sponsor
- Registry
-
NCT06249165
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT06249165. Randomized; no masking; primary purpose treatment. Start 2024-12-16 (actual); primary completion 2026-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease
- Acronym
- V-INCLUSION
- Condition
- Atherosclerotic Cardiovascular Disease
- Intervention (Drug)
- Inclisiran
- Lead sponsor
- Duke University
- Collaborator
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct06249165- Content hash
8ab2303f1e6397b10ce27199710f0e3008d84bc0a3e236256ca5cdc9d1c660e6